1.NCPC

In 2018, North China Pharmaceutical‘s (NCPC) operating revenue have reached 9.214 billion yuan, up 19.52% year on year. Influenced by market supply and demand, the company's sales volume and price of vitamins and nutrition and health products have increased. The operating revenue of this business segment has reached 440 million yuan, up 70.26% year on year. The gross profit margin of vitamins and nutritional health products was 22.09 percent, an increase of 0.91 percentage points over the same period last year.

2. Angel Yeast

In 2018, the company's operating revenue have reached 6.686 billion yuan, up 15.75 percent year-on-year, attributable to the parent company net profit of 857 million yuan, up 1.12% year on year, and the main factors drive this revenue growth is leading business continued to maintain good growth. During the reporting period, most of the company's business units achieved revenue growth and overall profitability. Among them, nutrition, health, microbial nutrition, plant nutrition, brewing and bio-energy, enzyme preparations income growth has exceeded 20%.

3. Yunnan Baiyao

In 2018, the company's operating revenue have reached 26.708 billion yuan, a net increase of 2.394 billion yuan from the previous year's 24.315 billion yuan, an increase of 9.84%. Net profit attributable to shareholders of listed companies was 3.307 billion yuan, an increase of 3.145 billion yuan over the same period of the previous year. 1.62 billion yuan, an increase of 5.14%. Among them, the company health products achieve the business income is 4.467 billion yuan, up 4.54% year on year. During the reporting period, the company efforts to cultivate and create new products, constantly digging intrinsic characteristics of products, refined new product selling.

4.H&H Group

In 2018, the group's revenue have reached 10.132 billion yuan, up 25.16 percent year-on-year. The profit attributable to the owner of the parent company was 843 million yuan, down 9.62% year on year, among which the group's adult nutrition and care products business revenue was 4.444 billion yuan, up 24.32% year on year. Probiotic supplements business revenue was 1.045 billion yuan, up 33.63% year on year. Swisse continue to invest in its core market, launching new product categories at the same time, extending new market. The growth was largely due to strong growth in the Chinese market, which accounted for 35.6% of total 2018 years of Swisse sales, while Swisse sales in the Australian market remained industry-leading, thereby increasing market share. Revenue from the Australian and New Zealand markets and active sales in China increased by 13.7% and 63.2% to 507.8 Australian dollars and 306.2 Australian dollars respectively last year.